Fatty Liver News and Research

Latest Fatty Liver News and Research

Mayo Clinic study: Reversing current thought on treatment of cirrhotic patients with type 2 diabetes

Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. The study found that the continuation of metformin after a cirrhosis diagnosis improved survival rates among diabetes patients.

19 Jun 2014

Healthy inflammation necessary to prevent metabolic diseases, study finds

Chronic tissue inflammation is typically associated with obesity and metabolic disease, but new research from UT-Southwestern Medical Center now finds that a level of "healthy" inflammation is necessary to prevent metabolic diseases, such as fatty liver.

19 Jun 2014

Common mutation in gene with overweight results in elevated ALAT values in children

A study carried out at the Institute of Biomedicine of the University of Eastern Finland shows that a common mutation in the PNPLA3 gene combined with overweight results in elevated ALAT values in children.

18 Jun 2014

Researchers find way to prevent nonalcoholic fatty liver disease

Studying mice, researchers have found a way to prevent nonalcoholic fatty liver disease, the most common cause of chronic liver disease worldwide.

4 Jun 2014

Researchers develop antibodies that reduce liver damage, recovers liver function

A Tainan-based research team from National Cheng Kung University (NCKU) has discovered the pathogenesis of liver fibrosis and developed antibodies that reduce liver damage, inhibit hepatic fibrosis, and recover liver function.

4 Jun 2014

Study examines how food additive MSG contributes to obesity and liver disease

The commonly used food additive monosodium glutamate (MSG) has been linked to obesity and disorders associated with the metabolic syndrome including progressive liver disease.

28 May 2014

Study identifies role of additive monosodium glutamate in obesity and liver disease

The commonly used food additive monosodium glutamate (MSG) has been linked to obesity and disorders associated with the metabolic syndrome including progressive liver disease.

28 May 2014

Hepatocellular carcinoma on the rise among Mexican Americans

Hepatocellular carcinoma (HCC), the primary cancer of the liver, is on the verge of becoming an epidemic among Mexican Americans, especially in Texas.

8 May 2014

Snacking linked with abdominal fat and fatty liver

Researchers from The Netherlands found that snacking on high-fat and high-sugar foods was independently associated with abdominal fat and fatty liver (hepatic steatosis).

7 May 2014

Rat pups exposed to tobacco smoke are at higher risk of developing metabolic disease

While many parents-to-be are aware that the health of their baby starts before they've actually arrived into the world, recent research reveals that "harm" (i.e., tobacco smoke, dirty air, poor nutrition, even preeclampsia) may not present itself disease-wise until well into adulthood or when a second harmful "hit" triggers the individual's susceptibility.

6 May 2014

Liver cancer screening in cirrhosis patients improves survival rates

Liver cancer survival rates could be improved if more people with cirrhosis are screened for tumors using inexpensive ultrasound scans and blood tests, according to a review by doctors at UT Southwestern Medical Center.

6 May 2014

Study shows reversal of early-stage liver fibrosis after bariatric surgery

Bariatric surgery, which is best known for its ability to help patients lose substantial weight, can also result in significant improvement in nonalcoholic fatty liver disease (NAFLD), according to new research presented today at Digestive Disease Week- (DDW).

5 May 2014

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society.

21 Apr 2014

UK study finds link between low vitamin D status and non-alcoholic fatty liver disease in British children

A UK study investigating the link between low vitamin D status and non-alcoholic fatty liver disease (NAFLD) in British children has identified a genetic variant associated with the disease's severity.

15 Apr 2014

Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Two new studies presented today at the International Liver CongressTM 2014 have provided more evidence to clarify the role of non-alcoholic fatty liver disease (NAFLD) as an independent risk factor for the development of cardiovascular disease (CVD).

10 Apr 2014

Drinking two or more cups of coffee each day reduces risk of death from liver cirrhosis by 66%

New research reveals that consuming two or more cups of coffee each day reduces the risk of death from liver cirrhosis by 66%, specifically cirrhosis caused by non-viral hepatitis. Findings in Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, show that tea, fruit juice, and soft drink consumption are not linked to cirrhosis mortality risk. As with previous studies heavy alcohol use was found to increase risk of death from cirrhosis.

2 Apr 2014

High levels of GDNF protein could help body resist weight gain despite high-fat diet

More than one-third of people in the US are obese. Obesity and its related health problems-including high blood pressure, high cholesterol, diabetes, insulin resistance, and belly fat-affect so many, yet effective treatments are very few.

2 Apr 2014

Expert highlights the importance of gender-specific approach for treating diabetes mellitus

The international guidelines on the drug-based therapy of diabetes mellitus specify which factors need to be taken into account during treatment.

27 Mar 2014

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

The progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD) is Non-Alcoholic Steatohepatitis (NASH), which defines a subgroup of NAFLD where liver steatosis co-exists with cell injury (hepatocyte ballooning) and inflammation with or without fibrosis at histological examination.

18 Mar 2014

Galmed Pharmaceuticals prices initial public offering of 2,837,400 shares

Galmed Pharmaceuticals Ltd. ("Galmed") today announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public offering price of $13.50 per share, before underwriting discounts and commissions.

13 Mar 2014

Fatty Liver News and Research

Latest Fatty Liver News and Research

Mayo Clinic study: Reversing current thought on treatment of cirrhotic patients with type 2 diabetes

Healthy inflammation necessary to prevent metabolic diseases, study finds

Common mutation in gene with overweight results in elevated ALAT values in children

Researchers find way to prevent nonalcoholic fatty liver disease

Researchers develop antibodies that reduce liver damage, recovers liver function

Study examines how food additive MSG contributes to obesity and liver disease

Study identifies role of additive monosodium glutamate in obesity and liver disease

Hepatocellular carcinoma on the rise among Mexican Americans

Snacking linked with abdominal fat and fatty liver

Rat pups exposed to tobacco smoke are at higher risk of developing metabolic disease

Liver cancer screening in cirrhosis patients improves survival rates

Study shows reversal of early-stage liver fibrosis after bariatric surgery

Synageva announces publication of LAL Deficiency review in Atherosclerosis

UK study finds link between low vitamin D status and non-alcoholic fatty liver disease in British children

Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Drinking two or more cups of coffee each day reduces risk of death from liver cirrhosis by 66%

High levels of GDNF protein could help body resist weight gain despite high-fat diet

Expert highlights the importance of gender-specific approach for treating diabetes mellitus

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

Galmed Pharmaceuticals prices initial public offering of 2,837,400 shares

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Fatty Liver News and Research

Latest Fatty Liver News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in